Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vetter Receives “Known Consignor” Approval from Germany's Federal Aviation Office

Published: Wednesday, December 12, 2012
Last Updated: Wednesday, December 12, 2012
Bookmark and Share
The CDMO meets new requirements six months ahead of deadline.

Vetter has announced that it has now been approved as a “Known Consignor” by the German Federal Aviation Office. The agency officially granted the pharmaceutical service provider the certificate of approval following an audit at Vetter´s Holbeinstrasse and Ravensburg Vetter West facilities.

The approval means that customers will continue to have their air cargo products loaded, transported and delivered quickly and safely, saving valuable time and money.

Vetter had already been designated as a “Known Consignor” back in 2006. The goal of the certification is primarily to provide more security for air cargo.

Until recently, logistics companies themselves issued the certificate. New EU regulations concerning the so-called "safe supply chains" require that companies must now have their status audited and approved by the Federal Aviation Office.

The criteria for certification are extensive and include elaborating a safety concept, training personnel, and the assurance that the shipping of freight is performed in a way that cannot be tampered with.

Any attempt to open the shipment would be immediately evident. The Federal Aviation Office grants the certificate for five years and carries out unannounced controls on a regular basis.

"Our approval as a "Known Consignor" allows our customers fast and smooth loading of air freight packages at the airport, including a high level of security,” said managing director Thomas Otto.

Otto continued, “Once time-consuming x-rays and searches are no longer necessary, saving invaluable effort and cost. For Vetter, the status of ”Known Consignor” is further proof of the high product quality that we offer our customers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vetter is a Winner of the AbbVie TRIUMPH AWARD
Company has received AbbVie TRIUMPH AWARD as a contract manufacturer in the category Third-Party Manufacturers - Supplier of the Year.
Thursday, May 12, 2016
Creation of a New 70 Million Euro Vetter Production Building
Company has announced that the new construction at a ground breaking ceremony represents an important component of a previously announced investment strategy.
Wednesday, March 23, 2016
Leading CDMO is Granted Both the Worldstar Award for Vetter-Ject® and a 2016 CMO Leadership Award
Company has announced that the worldStar competition is one of the major events of the WPO, and its award represents the pre-eminent international award in packaging.
Friday, February 19, 2016
Vetter Announces Completion of its Schuetzenstrasse Multi-Functional Building
2015 developments reflect another positive year of growth for the pharmaceutical service provider.
Sunday, January 31, 2016
Vetter Receives Internationally Recognized AEO-F Certificate
Pharmaceutical service providers and customers benefit from comprehensive tariff advantages.
Wednesday, December 02, 2015
Vetter Announces Office Opening in Japan
Company’s second office in the region will strengthen customer relations and help develop new business among emerging and established Japanese companies.
Thursday, October 15, 2015
Vetter Embarks on a 300 Million Euro Investment Strategy
Company will invest for further development to its manufacturing sites and to make available additional manufacturing capacities.
Thursday, October 01, 2015
Vetter Development Service Chicago Completes Recent On-Site Expansion Activities
Continued demand and increased customer product transfers are generating a positive business outlook for the company’s early-stage development facility.
Thursday, June 11, 2015
Vetter Serializes the First Product for South Korea
CDMO produces clearly identifiable labelling for a top-ten pharmaceutical company.
Saturday, May 02, 2015
Vetter Appoints Oliver Albrecht as Managing Director
Role with company commenced on April 1, 2015.
Thursday, April 09, 2015
Vetter Continues to Expand Capacity
Structural work completed on Vetter’s new multi-functional building for its Development Service and information technology (IT).
Friday, January 30, 2015
Vetter Adds Flexible Serialization Service to its Portfolio
A new service allowing for the explicit identification of drug packaging.
Thursday, December 04, 2014
Vetter Announces Opening of Office to Support Growing Asian Healthcare Market
New Asia Pacific office will support customer relations and the development of new business.
Friday, November 21, 2014
Vetter Announces Personnel Changes in its Development Service Division
Clinical manufacturing services continue to attract new business.
Saturday, October 18, 2014
Vetter Continues to Strengthen its Market Position
Another positive year for the CDMO.
Wednesday, January 15, 2014
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!